Editas Medicine Inc
For the period ended Dec 31, 2024. Filed Mar 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 5, 2025
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(amounts in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $131,541 | $123,652 |
| Marketable securities | 138,372 | 199,459 |
| Accounts receivable | 16,266 | 10,187 |
| Prepaid expenses and other current assets | 3,136 | 7,531 |
| Total current assets | 289,315 | 340,829 |
| Marketable securities | — | 104,024 |
| Property and equipment, net | 14,497 | 12,032 |
| Right-of-use assets | 32,554 | 33,680 |
| Restricted cash and other non-current assets | 5,223 | 8,588 |
| Total assets | $341,589 | $499,153 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $5,493 | $8,269 |
| Accrued expenses | 45,859 | 34,563 |
| Liability for sale of future revenues, current | 5,000 | — |
| Deferred revenue, current | 6,221 | 8,221 |
| Operating lease liabilities | 14,652 | 12,164 |
| Total current liabilities | 77,225 | 63,217 |
| Operating lease liabilities, net of current portion | 20,380 | 24,372 |
| Liability for sale of future revenues - non-current | 52,434 | — |
| Deferred revenue, net of current portion | 54,204 | 60,667 |
| Other non-current liabilities | 3,072 | 1,800 |
| Total liabilities | 207,315 | 150,056 |
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 82,734,696 and 81,767,263 shares issued, and 82,734,696 and 81,767,263 shares outstanding at December 31, 2024 and December 31, 2023, respectively | 8 | 8 |
| Additional paid-in capital | 1,602,441 | 1,580,241 |
| Accumulated other comprehensive income | 268 | 198 |
| Accumulated deficit | (1,468,443) | (1,231,350) |
| Total stockholders’ equity | 134,274 | 349,097 |
| Total liabilities and stockholders’ equity | $341,589 | $499,153 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.